Erratum: Laquinimod ameliorates spontaneous colitis in interleukin-10-gene-deficient mice with improved barrier function (International Immunopharmacology (2015) (423-432) DOI: 10.1016/j.intimp.2015.10.019);Laquinimod ameliorates spontaneous colitis in interleukin-10-gene-deficient mice with improved barrier function

International Immunopharmacology

Volumn 29, Issue 2, 2015, Pages 423-432

  Sun, Jing ^a   Shen, Xiao ^a   Dong, Jianning ^a   Zhao, Jie ^a   Zuo, Lugen ^a   Wang, Honggang ^a   Li, Yi ^a   Zhu, Weiming ^a   Gong, Jianfeng ^a   Li, Jieshou ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

Crohn's disease; IL 10 gene deficient mice; Intestinal barrier function; Laquinimod; NF B pathway

Indexed keywords

INTERLEUKIN 10; LAQUINIMOD; MESSENGER RNA; PROTEIN ZO1; TIGHT JUNCTION PROTEIN; CD45 ANTIGEN; CYTOKINE; IL10 PROTEIN, MOUSE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; QUINOLONE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLITIS; CONTROLLED STUDY; CROHN DISEASE; DISEASE SEVERITY; DRUG EFFICACY; LAMINA PROPRIA; LYMPHOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TH17 CELL; WILD TYPE; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; DEFICIENCY; DRUG EFFECTS; GENETICS; INTESTINE MUCOSA; KNOCKOUT MOUSE; LYMPHOCYTE COUNT; METABOLISM; PERMEABILITY;

ANIMALS; ANTIGENS, CD45; COLITIS; CROHN DISEASE; CYTOKINES; INTERLEUKIN-10; INTESTINAL MUCOSA; LYMPHOCYTE COUNT; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NF-KAPPA B; PERMEABILITY; QUINOLONES;

EID: 84948455050     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2016.03.012     Document Type: Erratum

References (45)

1. S.Y. Salim, and J.D. Soderholm Importance of disrupted intestinal barrier in inflammatory bowel diseases Inflamm. Bowel Dis. 17 2011 362 381
2. D.C. Baumgart, and W.J. Sandborn Crohn's disease Lancet 380 2012 1590 1605
3. J.F. Colombel, A.J. Watson, and M.F. Neurath The 10 remaining mysteries of inflammatory bowel disease Gut 57 2008 429 433
4. L. Shen Tight junctions on the move: molecular mechanisms for epithelial barrier regulation Ann. N. Y. Acad. Sci. 1258 2012 9 18
5. J.B. Ewaschuk, H. Diaz, L. Meddings, and et al. Secreted bioactive factors from Bifidobacterium infantis enhance epithelial cell barrier function Am. J. Physiol. Gastrointest. Liver Physiol. 295 2008 G1025 G1034
6. J.R. Turner Molecular basis of epithelial barrier regulation: from basic mechanisms to clinical application Am. J. Pathol. 169 2006 1901 1909
7. J. Madara Regulation of the movement of solutes across tight junctions Annu. Rev. Physiol. 60 1998 143 159
8. J.R. Turner Intestinal mucosal barrier function in health and disease Nat. Rev. Immunol. 9 2009 799 809
9. S. Brand Crohn's disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn's disease Gut 58 2009 1152 1167
10. P.P. Ahern, A. Izcue, K.J. Maloy, and et al. The interleukin-23 axis in intestinal inflammation Immunol. Rev. 226 2008 147 159
11. J.A. Goettel, H.M. Scott Algood, D. Olivares-Villagomez, and et al. KSR1 protects from interleukin-10 deficiency-induced colitis in mice by suppressing T-lymphocyte interferon-gamma production Gastroenterology 140 2011 265 274
12. R. Kuhn, J. Lohler, D. Rennick, and et al. Interleukin-10-deficient mice develop chronic enterocolitis Cell 75 1993 263 274
13. A.C. Gomes-Santos, T.G. Moreira, A.B. Castro-Junior, and et al. New insights into the immunological changes in IL-10-deficient mice during the course of spontaneous inflammation in the gut mucosa Clin. Dev. Immunol. 2012 2012 560817
14. G. Comi, D. Jeffery, L. Kappos, and et al. Placebo-controlled trial of oral laquinimod for multiple sclerosis N. Engl. J. Med. 366 2012 1000 1009
15. J.S. Yang, L.Y. Xu, B.G. Xiao, and et al. Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats J. Neuroimmunol. 156 2004 3 9
16. E.V. Lourenço, M. Wong, and B.H. Hahn Laquinimod delays and suppresses nephritis in lupus-prone mice and affects both myeloid and lymphoid immune cells Arthritis Rheum 66 2014 674 685
17. D.E. Elliott, T. Setiawan, A. Metwali, and et al. Heligmosomoides polygyrus inhibits established colitis in IL-10-deficient mice Eur. J. Immunol. 34 2004 2690 2698
18. M.R. Etling, S. Davies, M. Campbell, and et al. Maturation of the mucosal immune system underlies colitis susceptibility in interleukin-10-deficient (IL-10 -/-) mice J. Leukoc. Biol. 82 2007 311 319
19. U.P. Singh, S. Singh, D.D. Taub, and et al. Inhibition of IFN-gamma-inducible protein-10 abrogates colitis in IL-10 -/- mice J. Immunol. 171 2003 1401 1406
20. M.C. Arrieta, K. Madsen, J. Doyle, and et al. Reducing small intestinal permeability attenuates colitis in the IL10 gene-deficient mouse Gut 58 2009 41 48
21. H. Wang, W. Zhang, L. Zuo, and et al. Bifidobacteria may be beneficial to intestinal microbiota and reduction of bacterial translocation in mice following ischaemia and reperfusion injury Br. J. Nutr. 109 2013 1990 1998
22. D.R. Clayburgh, T.A. Barrett, Y. Tang, and et al. Epithelial myosin light chain kinase-dependent barrier dysfunction mediates T cell activation-induced diarrhea in vivo J. Clin. Invest. 115 2005 2702 2715
23. E. Esplugues, S. Huber, N. Gagliani, and et al. Control of TH17 cells occurs in the small intestine Nature 475 2011 514 518
24. S.Z. Ke, X.Y. Ni, Y.H. Zhang, and et al. Camptothecin and cisplatin upregulate ABCG2 and MRP2 expression by activating the ATM/NF-kappaB pathway in lung cancer cells Int. J. Oncol. 42 4 2013 1289 1296
25. Y.T. Cheng, S.L. Wu, C.Y. Ho, and et al. Beneficial effects of camellia oil (Camellia oleifera Abel.) on ketoprofen-induced gastrointestinal mucosal damage through upregulation of HO-1 and VEGF J. Agric. Food Chem. 62 3 2014 642 650
26. D. Yen, J. Cheung, H. Scheerens, and et al. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6 J. Clin. Invest. 116 2006 1310 1316
27. A.J. Watson, and K.R. Hughes TNF-alpha-induced intestinal epithelial cell shedding: implications for intestinal barrier function Ann. N. Y. Acad. Sci. 1258 2012 1 8
28. H. Schmitz, M. Fromm, C.J. Bentzel, and et al. Tumor necrosis factor-alpha (TNF-α) regulates the epithelial barrier in the human intestinal cell line HT-29/B6 J. Cell Sci. 112 1999 137 146
29. R.M. Al-Sadi, and T.Y. Ma IL-1beta causes an increase in intestinal epithelial tight junction permeability J. Immunol. 178 2007 4641 4649
30. M.T. Midura-Kiela, V.M. Radhakrishnan, C.B. Larmonier, and et al. Curcumin inhibits interferon-γ signaling in colonic epithelial cells Am. J. Physiol. Gastrointest. Liver Physiol. 302 1 2012 G85 G96
31. T. Kinugasa, T. Sakaguchi, X. Gu, and et al. Claudins regulate the intestinal barrier in response to immune mediators Gastroenterology 118 2000 1001 1011
32. W. Brück, R. Pförtner, T. Pham, and et al. Reduced astrocytic NF-κB activation by laquinimod protects from cuprizone-induced demyelination Acta Neuropathol. 124 2012 411 424
33. R. Al-Sadi, D. Ye, H.M. Said, and et al. IL-1beta-induced increase in intestinal epithelial tight junction permeability is mediated by MEKK-1 activation of canonical NF-kappaB pathway Am. J. Pathol. 177 2010 2310 2322
34. A. Saadane, J. Soltys, and M. Berger Role of IL-10 deficiency in excessive nuclear factor-kappaB activation and lung inflammation in cystic fibrosis transmembrane conductance regulator knockout mice J. Allergy Clin. Immunol. 115 2005 405 411
35. H. Oh, and S. Ghosh NF-κB: roles and regulation in different CD4 + T-cell subsets Immunol. Rev. 252 2013 41 51
36. V. Jolivel, F. Luessi, J. Masri, and et al. Modulation of dendritic cell properties by laquinimod as a mechanism for modulating multiple sclerosis Brain 136 2013 1048 1066
37. M.A. Aronica, A.L. Mora, D.B. Mitchell, and et al. Preferential role for NF-kappa B/Rel signaling in the type 1 but not type 2 T cell-dependent immune response in vivo J. Immunol. 163 1999 5116 5124
38. Q. Ruan, V. Kameswaran, Y. Zhang, and et al. The Th17 immune response is controlled by the Rel-RORgamma-RORgamma T transcriptional axis J. Exp. Med. 208 2011 2321 2333
39. J.M. Muller, H.W. Ziegler-Heitbrock, and P.A. Baeuerle Nuclear factor kappa B, a mediator of lipopolysaccharide effects Immunobiology 187 1993 233 256
40. S. Maeda, L.C. Hsu, H. Liu, and et al. Nod2 mutation in Crohn's disease potentiates NF-κB activity and IL-1β processing Science 307 2005 734 738
41. E. Prefontaine, L.R. Sutherland, J.K. Macdonald, and et al. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease Cochrane Database Syst. Rev. 21 2009 CD000067
42. S. Ardizzone, G. Maconi, G.M. Sampietro, and et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease Gastroenterology 127 2004 730 740
43. M. Gurevich, T. Gritzman, R. Orbach, and et al. Laquinimod suppress antigen presentation in relapsing-remitting multiple sclerosis: in-vitro high-throughput gene expression study J. Neuroimmunol. 221 2010 87 94
44. J. Killestein, R.A. Rudick, and C.H. Polman Oral treatment for multiple sclerosis Lancet Neurol. 10 2011 1026 1034
45. G. D'Haens, W.J. Sandborn, J.F. Colombel, and et al. Laquinimod for Crohn's disease investigators. A phase II study of laquinimod in Crohn's disease Gut 64 2015 1227 1235